{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:51:35Z","timestamp":1793213495901,"version":"4.5.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00702-025-02955-7","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T06:27:58Z","timestamp":1748586478000},"page":"843-852","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A narrative review of serum biomarkers in progressive supranuclear palsy, corticobasal syndrome, and related disorders"],"prefix":"10.1007","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7787-9979","authenticated-orcid":false,"given":"Alexandros","family":"Giannakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spiridon","family":"Konitsiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrissa","family":"Sioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"2955_CR1","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1136\/jnnp-2013-307035","volume":"85","author":"SK Alexander","year":"2014","unstructured":"Alexander SK, Rittman T, Xuereb JH et al (2014) Validation of the new consensus criteria for the diagnosis of corticobasal degeneration. J Neurol Neurosurg Psychiatry 85:925\u2013929. https:\/\/doi.org\/10.1136\/jnnp-2013-307035","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2955_CR2","doi-asserted-by":"publisher","unstructured":"Alster P, Otto-\u015alusarczyk D, Kuty\u0142owski M et al (2024) The associations between common neuroimaging parameters of progressive supranuclear palsy in magnetic resonance imaging and non-specific inflammatory factors\u2013 pilot study. Front Immunol 15. https:\/\/doi.org\/10.3389\/fimmu.2024.1458713","DOI":"10.3389\/fimmu.2024.1458713"},{"key":"2955_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11910-018-0819-5","volume":"18","author":"MJ Armstrong","year":"2018","unstructured":"Armstrong MJ (2018) Progressive supranuclear palsy: an update. Curr Neurol Neurosci Rep 18:12. https:\/\/doi.org\/10.1007\/s11910-018-0819-5","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2955_CR4","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","volume":"80","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong MJ, Litvan I, Lang AE et al (2013) Criteria for the diagnosis of corticobasal degeneration. Neurology 80:496\u2013503. https:\/\/doi.org\/10.1212\/WNL.0b013e31827f0fd1","journal-title":"Neurology"},{"key":"2955_CR5","doi-asserted-by":"publisher","unstructured":"Assogna M, Premi E, Gazzina S et al (2023) Association of choroid plexus volume with serum biomarkers, clinical features, and disease severity in patients with frontotemporal Lobar degeneration spectrum. Neurology 101. https:\/\/doi.org\/10.1212\/WNL.0000000000207600","DOI":"10.1212\/WNL.0000000000207600"},{"key":"2955_CR6","doi-asserted-by":"publisher","unstructured":"Baiardi S, Quadalti C, Mammana A et al (2022) Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias. Alzheimers Res Ther 14. https:\/\/doi.org\/10.1186\/s13195-022-01093-6","DOI":"10.1186\/s13195-022-01093-6"},{"key":"2955_CR7","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3233\/JAD-200608","volume":"77","author":"A Benussi","year":"2020","unstructured":"Benussi A, Ashton NJ, Karikari TK et al (2020) Serum glial fibrillary acidic protein (GFAP) is a marker of disease severity in frontotemporal Lobar degeneration. J Alzheimer\u2019s Disease 77:1129\u20131141. https:\/\/doi.org\/10.3233\/JAD-200608","journal-title":"J Alzheimer\u2019s Disease"},{"key":"2955_CR8","doi-asserted-by":"publisher","first-page":"106978","DOI":"10.1016\/j.parkreldis.2024.106978","volume":"123","author":"MG Bianco","year":"2024","unstructured":"Bianco MG, Cristiani CM, Scaramuzzino L et al (2024) Combined blood neurofilament light chain and third ventricle width to differentiate progressive supranuclear palsy from Parkinson\u2019s disease: A machine learning study. Parkinsonism Relat Disord 123:106978. https:\/\/doi.org\/10.1016\/j.parkreldis.2024.106978","journal-title":"Parkinsonism Relat Disord"},{"key":"2955_CR9","doi-asserted-by":"publisher","unstructured":"Chen Y, Wang Y, Tao Q et al (2024) Diagnostic value of isolated plasma biomarkers and its combination in neurodegenerative dementias: A multicenter cohort study. Clin Chim Acta 558. https:\/\/doi.org\/10.1016\/j.cca.2024.118784","DOI":"10.1016\/j.cca.2024.118784"},{"key":"2955_CR10","doi-asserted-by":"publisher","first-page":"54215","DOI":"10.18632\/oncotarget.11090","volume":"7","author":"C-C Chiu","year":"2016","unstructured":"Chiu C-C, Yeh T-H, Lai S-C et al (2016) Increased Rab35 expression is a potential biomarker and implicated in the pathogenesis of Parkinson\u2019s disease. Oncotarget 7:54215\u201354227. https:\/\/doi.org\/10.18632\/oncotarget.11090","journal-title":"Oncotarget"},{"key":"2955_CR11","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1111\/ane.12012","volume":"127","author":"R Constantinescu","year":"2013","unstructured":"Constantinescu R, Andreasson U, Holmberg B, Zetterberg H (2013) Serum and cerebrospinal fluid urate levels in synucleinopathies versus tauopathies. Acta Neurol Scand 127:e8\u2013e12. https:\/\/doi.org\/10.1111\/ane.12012","journal-title":"Acta Neurol Scand"},{"key":"2955_CR12","doi-asserted-by":"publisher","first-page":"11663","DOI":"10.3390\/ijms252111663","volume":"25","author":"CM Cristiani","year":"2024","unstructured":"Cristiani CM, Calomino C, Scaramuzzino L et al (2024a) Proximity elongation assay and ELISA for the identification of serum diagnostic biomarkers in Parkinson\u2019s disease and progressive supranuclear palsy. Int J Mol Sci 25:11663. https:\/\/doi.org\/10.3390\/ijms252111663","journal-title":"Int J Mol Sci"},{"key":"2955_CR13","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.3390\/diagnostics14232746","volume":"14","author":"CM Cristiani","year":"2024","unstructured":"Cristiani CM, Scaramuzzino L, Parrotta EI et al (2024b) Serum Tau species in progressive supranuclear palsy: A pilot study. Diagnostics 14:2746. https:\/\/doi.org\/10.3390\/diagnostics14232746","journal-title":"Diagnostics"},{"key":"2955_CR14","doi-asserted-by":"publisher","unstructured":"Cristiani CM, Scaramuzzino L, Quattrone A et al (2024c) Serum oligomeric \u03b1-Synuclein and p-tau181 in progressive supranuclear palsy and Parkinson\u2019s disease. Int J Mol Sci 25. https:\/\/doi.org\/10.3390\/ijms25136882","DOI":"10.3390\/ijms25136882"},{"key":"2955_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s11940-024-00797-4","volume":"26","author":"C Delpirou Nouh","year":"2024","unstructured":"Delpirou Nouh C, Younes K (2024) Diagnosis and management of progressive corticobasal syndrome. Curr Treat Options Neurol 26:319\u2013338. https:\/\/doi.org\/10.1007\/s11940-024-00797-4","journal-title":"Curr Treat Options Neurol"},{"key":"2955_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.4103\/aian.aian_507_23","volume":"27","author":"S Dey","year":"2024","unstructured":"Dey S, Yelamanchi R, Mullapudi T et al (2024) Association of Insulin-like growth Factor-1 and neurofilament light chain in patients with progressive supranuclear palsy. Ann Indian Acad Neurol 27:40\u201345. https:\/\/doi.org\/10.4103\/aian.aian_507_23","journal-title":"Ann Indian Acad Neurol"},{"key":"2955_CR17","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.parkreldis.2018.06.018","volume":"56","author":"L Donker Kaat","year":"2018","unstructured":"Donker Kaat L, Meeter LH, Chiu WZ et al (2018) Serum neurofilament light chain in progressive supranuclear palsy. Parkinsonism Relat Disord 56:98\u2013101. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.06.018","journal-title":"Parkinsonism Relat Disord"},{"key":"2955_CR18","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/j.1471-4159.2007.04968.x","volume":"104","author":"JL Eriksen","year":"2008","unstructured":"Eriksen JL, Mackenzie IRA (2008) Progranulin: normal function and role in neurodegeneration. J Neurochem 104:287\u2013297. https:\/\/doi.org\/10.1111\/j.1471-4159.2007.04968.x","journal-title":"J Neurochem"},{"key":"2955_CR19","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/S1474-4422(23)00447-7","volume":"23","author":"GB Frisoni","year":"2024","unstructured":"Frisoni GB, Festari C, Massa F et al (2024) European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders. Lancet Neurol 23:302\u2013312. https:\/\/doi.org\/10.1016\/S1474-4422(23)00447-7","journal-title":"Lancet Neurol"},{"key":"2955_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jns.2016.04.042","volume":"366","author":"Y Fukui","year":"2016","unstructured":"Fukui Y, Hishikawa N, Shang J et al (2016) Peripheral arterial endothelial dysfunction of neurodegenerative diseases. J Neurol Sci 366:94\u201399. https:\/\/doi.org\/10.1016\/j.jns.2016.04.042","journal-title":"J Neurol Sci"},{"key":"2955_CR21","doi-asserted-by":"publisher","first-page":"111099","DOI":"10.1016\/j.jocn.2025.111099","volume":"134","author":"A Giannakis","year":"2025","unstructured":"Giannakis A, Konitsiotis S (2025) A new paradigm for neurodegenerative diseases classification: A clinical perspective. J Clin Neurosci 134:111099. https:\/\/doi.org\/10.1016\/j.jocn.2025.111099","journal-title":"J Clin Neurosci"},{"key":"2955_CR22","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3390\/medicina61040701","volume":"61","author":"A Giannakis","year":"2025","unstructured":"Giannakis A, Konitsiotis S, Sioka C (2025) Differentiating progressive supranuclear palsy and corticobasal syndrome: insights from cerebrospinal fluid Biomarkers\u2014A. Narrative Rev Med (B Aires) 61:701. https:\/\/doi.org\/10.3390\/medicina61040701","journal-title":"Narrative Rev Med (B Aires)"},{"key":"2955_CR23","doi-asserted-by":"publisher","first-page":"105937","DOI":"10.1016\/j.nbd.2022.105937","volume":"176","author":"K G\u00f6tze","year":"2023","unstructured":"G\u00f6tze K, Vrillon A, Bouaziz-Amar E et al (2023) Plasma neurofilament light chain in memory clinic practice: evidence from a real-life study. Neurobiol Dis 176:105937. https:\/\/doi.org\/10.1016\/j.nbd.2022.105937","journal-title":"Neurobiol Dis"},{"key":"2955_CR24","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1002\/mds.27666","volume":"34","author":"M Grimm","year":"2019","unstructured":"Grimm M, Respondek G, Stamelou M et al (2019) How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Mov Disord 34:1228\u20131232. https:\/\/doi.org\/10.1002\/mds.27666","journal-title":"Mov Disord"},{"key":"2955_CR25","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1515\/revneuro-2018-0061","volume":"30","author":"S-C Gu","year":"2019","unstructured":"Gu S-C, Ye Q, Yuan C-X (2019) Metabolic pattern analysis of 18 F-FDG PET as a marker for Parkinson\u2019s disease: a systematic review and meta-analysis. Rev Neurosci 30:743\u2013756. https:\/\/doi.org\/10.1515\/revneuro-2018-0061","journal-title":"Rev Neurosci"},{"key":"2955_CR26","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","volume":"88","author":"O Hansson","year":"2017","unstructured":"Hansson O, Janelidze S, Hall S et al (2017) Blood-based NfL. Neurology 88:930\u2013937. https:\/\/doi.org\/10.1212\/WNL.0000000000003680","journal-title":"Neurology"},{"key":"2955_CR27","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU H\u00f6glinger","year":"2017","unstructured":"H\u00f6glinger GU, Respondek G, Stamelou M et al (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 32:853\u2013864. https:\/\/doi.org\/10.1002\/mds.26987","journal-title":"Mov Disord"},{"key":"2955_CR28","doi-asserted-by":"publisher","first-page":"112366","DOI":"10.1016\/j.exger.2024.112366","volume":"187","author":"J Huang","year":"2024","unstructured":"Huang J, Yuan X, Chen L et al (2024) Pathological \u03b1-synuclein detected by real-time quaking-induced conversion in synucleinopathies. Exp Gerontol 187:112366. https:\/\/doi.org\/10.1016\/j.exger.2024.112366","journal-title":"Exp Gerontol"},{"key":"2955_CR29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1001\/jamaneurol.2019.4347","volume":"77","author":"E Jabbari","year":"2020","unstructured":"Jabbari E, Holland N, Chelban V et al (2020) Diagnosis across the spectrum of progressive supranuclear palsy and corticobasal syndrome. JAMA Neurol 77:377\u2013387. https:\/\/doi.org\/10.1001\/jamaneurol.2019.4347","journal-title":"JAMA Neurol"},{"key":"2955_CR30","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack","year":"2024","unstructured":"Jack CR, Andrews JS, Beach TG et al (2024) Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s association workgroup. Alzheimer\u2019s Dement 20:5143\u20135169. https:\/\/doi.org\/10.1002\/alz.13859","journal-title":"Alzheimer\u2019s Dement"},{"key":"2955_CR31","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1136\/jnnp-2019-322588","volume":"91","author":"C Jiang","year":"2020","unstructured":"Jiang C, Hopfner F, Katsikoudi A et al (2020) Serum neuronal exosomes predict and differentiate Parkinson\u2019s disease from atypical parkinsonism. J Neurol Neurosurg Psychiatry 91:720\u2013729. https:\/\/doi.org\/10.1136\/jnnp-2019-322588","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2955_CR32","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1021\/acschemneuro.3c00611","volume":"15","author":"M Kaleta","year":"2024","unstructured":"Kaleta M, H\u00e9nykov\u00e1 E, Men\u0161\u00edkov\u00e1 K et al (2024) Patients with neurodegenerative proteinopathies exhibit altered Tryptophan metabolism in the serum and cerebrospinal fluid. ACS Chem Neurosci 15:582\u2013592. https:\/\/doi.org\/10.1021\/acschemneuro.3c00611","journal-title":"ACS Chem Neurosci"},{"key":"2955_CR33","doi-asserted-by":"publisher","unstructured":"Khosousi S, Hye A, Velayudhan L et al (2023) Complement system changes in blood in Parkinson\u2019s disease and progressive supranuclear palsy\/corticobasal syndrome. https:\/\/doi.org\/10.1016\/j.parkreldis.2023.105313. Parkinsonism Relat Disord 108:","DOI":"10.1016\/j.parkreldis.2023.105313"},{"key":"2955_CR34","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/jnc.15944","volume":"167","author":"D Kon\u00ed\u010dkov\u00e1","year":"2023","unstructured":"Kon\u00ed\u010dkov\u00e1 D, Men\u0161\u00edkov\u00e1 K, Kl\u00ed\u010dov\u00e1 K et al (2023) Cerebrospinal fluid and blood serum biomarkers in neurodegenerative proteinopathies: A prospective, open, <scp\u2009>\u2009cross-correlation\u2009study<\/scp\u2009>. J Neurochem 167:168\u2013182. https:\/\/doi.org\/10.1111\/jnc.15944","journal-title":"J Neurochem"},{"key":"2955_CR35","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3390\/cells10030656","volume":"10","author":"D Koziorowski","year":"2021","unstructured":"Koziorowski D, Figura M, Milanowski \u0141M et al (2021) Mechanisms of neurodegeneration in various forms of Parkinsonism\u2014Similarities and differences. Cells 10:656. https:\/\/doi.org\/10.3390\/cells10030656","journal-title":"Cells"},{"key":"2955_CR36","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrg2843","volume":"11","author":"J Krol","year":"2010","unstructured":"Krol J, Loedige I, Filipowicz W (2010) The widespread regulation of MicroRNA biogenesis, function and decay. Nat Rev Genet 11:597\u2013610. https:\/\/doi.org\/10.1038\/nrg2843","journal-title":"Nat Rev Genet"},{"key":"2955_CR37","doi-asserted-by":"publisher","first-page":"107155","DOI":"10.1016\/j.parkreldis.2024.107155","volume":"129","author":"IH Kwak","year":"2024","unstructured":"Kwak IH, Kim YE, Kim YJ et al (2024) Monocyte to high-density lipoprotein cholesterol ratio reflects the peripheral inflammatory state in parkinsonian disorders. Parkinsonism Relat Disord 129:107155. https:\/\/doi.org\/10.1016\/j.parkreldis.2024.107155","journal-title":"Parkinsonism Relat Disord"},{"key":"2955_CR38","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S1474","volume":"10","author":"JJ Locascio","year":"2011","unstructured":"Locascio JJ, Schulz-Schaeff W, Mollenhauer B et al (2011) \u03b1-Synuclein and Tau concentrations in cerebrospinal Fl Uid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 10:230\u2013240. https:\/\/doi.org\/10.1016\/S1474","journal-title":"Lancet Neurol"},{"key":"2955_CR39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.parkreldis.2020.05.033","volume":"77","author":"S Mangesius","year":"2020","unstructured":"Mangesius S, Mariotto S, Ferrari S et al (2020) Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers. Parkinsonism Relat Disord 77:57\u201363. https:\/\/doi.org\/10.1016\/j.parkreldis.2020.05.033","journal-title":"Parkinsonism Relat Disord"},{"key":"2955_CR40","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.parkreldis.2021.11.020","volume":"93","author":"I Manna","year":"2021","unstructured":"Manna I, Quattrone A, De Benedittis S et al (2021) Exosomal MiRNA as peripheral biomarkers in Parkinson\u2019s disease and progressive supranuclear palsy: A pilot study. Parkinsonism Relat Disord 93:77\u201384. https:\/\/doi.org\/10.1016\/j.parkreldis.2021.11.020","journal-title":"Parkinsonism Relat Disord"},{"key":"2955_CR41","doi-asserted-by":"publisher","unstructured":"Marques TM, van Rumund A, Oeckl P et al (2019) Serum NFL discriminates Parkinson disease from atypical parkinsonisms. Neurology 92. https:\/\/doi.org\/10.1212\/WNL.0000000000007179","DOI":"10.1212\/WNL.0000000000007179"},{"key":"2955_CR42","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW et al (2017) Diagnosis and management of dementia with lewy bodies. Neurology 89:88\u2013100. https:\/\/doi.org\/10.1212\/WNL.0000000000004058","journal-title":"Neurology"},{"key":"2955_CR43","doi-asserted-by":"publisher","unstructured":"Meloni M, Agliardi C, Guerini FR et al (2023) Oligomeric \u03b1-synuclein and Tau aggregates in NDEVs differentiate Parkinson\u2019s disease from atypical parkinsonisms. Neurobiol Dis 176. https:\/\/doi.org\/10.1016\/j.nbd.2022.105947","DOI":"10.1016\/j.nbd.2022.105947"},{"key":"2955_CR44","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3233\/JAD-2008-14106","volume":"14","author":"M Menendez-Gonzalez","year":"2008","unstructured":"Menendez-Gonzalez M, Castro-Santos P, Suarez A et al (2008) Value of measuring plasmatic levels of neurosin in the diagnosis of Alzheimer\u2019s disease. J Alzheimer\u2019s Disease 14:59\u201367. https:\/\/doi.org\/10.3233\/JAD-2008-14106","journal-title":"J Alzheimer\u2019s Disease"},{"key":"2955_CR45","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S0891-5849(00)00503-7","volume":"30","author":"A Mitsumoto","year":"2001","unstructured":"Mitsumoto A, Takanezawa Y, Okawa K et al (2001) Variants of Peroxiredoxins expression in response to hydroperoxide stress. Free Radic Biol Med 30:625\u2013635. https:\/\/doi.org\/10.1016\/S0891-5849(00)00503-7","journal-title":"Free Radic Biol Med"},{"key":"2955_CR46","doi-asserted-by":"publisher","first-page":"e0223113","DOI":"10.1371\/journal.pone.0223113","volume":"14","author":"A Mori","year":"2019","unstructured":"Mori A, Ishikawa K-I, Saiki S et al (2019) Plasma metabolite biomarkers for multiple system atrophy and progressive supranuclear palsy. PLoS ONE 14:e0223113. https:\/\/doi.org\/10.1371\/journal.pone.0223113","journal-title":"PLoS ONE"},{"key":"2955_CR47","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/mds.26466","volume":"31","author":"JM Oropesa-Ruiz","year":"2016","unstructured":"Oropesa-Ruiz JM, Huertas-Fern\u00e1ndez I, Jes\u00fas S et al (2016) Low serum uric acid levels in progressive supranuclear palsy. Mov Disord 31:402\u2013405. https:\/\/doi.org\/10.1002\/mds.26466","journal-title":"Mov Disord"},{"key":"2955_CR48","doi-asserted-by":"publisher","unstructured":"Pavelka L, Rauschenberger A, Hemedan A et al (2024) Converging peripheral blood MicroRNA profiles in Parkinson\u2019s disease and progressive supranuclear palsy. Brain Commun 6. https:\/\/doi.org\/10.1093\/braincomms\/fcae187","DOI":"10.1093\/braincomms\/fcae187"},{"key":"2955_CR49","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.3390\/diagnostics12051204","volume":"12","author":"P Ramaswamy","year":"2022","unstructured":"Ramaswamy P, Christopher R, Kumar Pal P et al (2022) Plasma MicroRNAs as a potential biomarker for identification of progressive supranuclear palsy. Diagnostics 12:1204. https:\/\/doi.org\/10.3390\/diagnostics12051204","journal-title":"Diagnostics"},{"key":"2955_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s42466-023-00294-0","volume":"6","author":"G Remoli","year":"2024","unstructured":"Remoli G, Schilke ED, Magi A et al (2024) Neuropathological hints from CSF and serum biomarkers in corticobasal syndrome (CBS): a systematic review. Neurol Res Pract 6:1. https:\/\/doi.org\/10.1186\/s42466-023-00294-0","journal-title":"Neurol Res Pract"},{"key":"2955_CR51","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1002\/mds.27034","volume":"32","author":"G Respondek","year":"2017","unstructured":"Respondek G, Kurz C, Arzberger T et al (2017) Which ante mortem clinical features predict progressive supranuclear palsy pathology? Mov Disord 32:995\u20131005. https:\/\/doi.org\/10.1002\/mds.27034","journal-title":"Mov Disord"},{"key":"2955_CR52","doi-asserted-by":"crossref","unstructured":"Saeed U, Lang AE, Masellis M (2020) Neuroimaging advances in Parkinson\u2019s disease and atypical parkinsonian syndromes. Front Neurol 11","DOI":"10.3389\/fneur.2020.572976"},{"key":"2955_CR53","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3233\/JAD-2010-101032","volume":"22","author":"EC Schofield","year":"2010","unstructured":"Schofield EC, Halliday GM, Kwok J et al (2010) Low serum progranulin predicts the presence of mutations: A prospective study. J Alzheimer\u2019s Disease 22:981\u2013984. https:\/\/doi.org\/10.3233\/JAD-2010-101032","journal-title":"J Alzheimer\u2019s Disease"},{"key":"2955_CR54","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1002\/mds.28738","volume":"36","author":"I Schulz","year":"2021","unstructured":"Schulz I, Kruse N, Gera RG et al (2021) Systematic assessment of 10 biomarker candidates focusing on \u03b1-Synuclein\u2010Related disorders. Mov Disord 36:2874\u20132887. https:\/\/doi.org\/10.1002\/mds.28738","journal-title":"Mov Disord"},{"key":"2955_CR55","doi-asserted-by":"publisher","first-page":"14554","DOI":"10.3390\/ijms232314554","volume":"23","author":"FA Simoes","year":"2022","unstructured":"Simoes FA, Joilin G, Peters O et al (2022) Potential of Non-Coding RNA as biomarkers for progressive supranuclear palsy. Int J Mol Sci 23:14554. https:\/\/doi.org\/10.3390\/ijms232314554","journal-title":"Int J Mol Sci"},{"key":"2955_CR56","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1093\/brain\/awl267","volume":"129","author":"JS Snowden","year":"2006","unstructured":"Snowden JS, Pickering-Brown SM, Mackenzie IR et al (2006) Progranulin gene mutations associated with frontotemporal dementia and progressive non-fluent aphasia. Brain 129:3091\u20133102. https:\/\/doi.org\/10.1093\/brain\/awl267","journal-title":"Brain"},{"key":"2955_CR58","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen EH, La Joie R, Wolf A et al (2020) Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal Lobar degeneration. Nat Med 26:387\u2013397. https:\/\/doi.org\/10.1038\/s41591-020-0762-2","journal-title":"Nat Med"},{"key":"2955_CR57","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","volume":"20","author":"EH Thijssen","year":"2021","unstructured":"Thijssen EH, La Joie R, Strom A et al (2021) Plasma phosphorylated Tau 217 and phosphorylated Tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal Lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol 20:739\u2013752. https:\/\/doi.org\/10.1016\/S1474-4422(21)00214-3","journal-title":"Lancet Neurol"},{"key":"2955_CR59","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3988\/jcn.2019.15.4.488","volume":"15","author":"H-L Wang","year":"2019","unstructured":"Wang H-L, Lu C-S, Yeh T-H et al (2019) Combined assessment of serum Alpha-Synuclein and Rab35 is a better biomarker for Parkinson\u2019s disease. J Clin Neurol 15:488. https:\/\/doi.org\/10.3988\/jcn.2019.15.4.488","journal-title":"J Clin Neurol"},{"key":"2955_CR60","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.ajhg.2014.10.015","volume":"95","author":"GR Wilson","year":"2014","unstructured":"Wilson GR, Sim JCH, McLean C et al (2014) Mutations in RAB39B cause X-Linked intellectual disability and Early-Onset Parkinson disease with \u03b1-Synuclein pathology. Am J Hum Genet 95:729\u2013735. https:\/\/doi.org\/10.1016\/j.ajhg.2014.10.015","journal-title":"Am J Hum Genet"},{"key":"2955_CR61","doi-asserted-by":"publisher","unstructured":"Wise A, Li J, Yamakawa M et al (2024) CSF proteomics in patients with progressive supranuclear palsy. https:\/\/doi.org\/10.1212\/WNL.0000000000209585. Neurology 103:","DOI":"10.1212\/WNL.0000000000209585"},{"key":"2955_CR62","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.neures.2017.06.008","volume":"128","author":"Y Yamagishi","year":"2018","unstructured":"Yamagishi Y, Saigoh K, Saito Y et al (2018) Diagnosis of Parkinson\u2019s disease and the level of oxidized DJ-1 protein. Neurosci Res 128:58\u201362. https:\/\/doi.org\/10.1016\/j.neures.2017.06.008","journal-title":"Neurosci Res"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-02955-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-025-02955-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-02955-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T11:51:50Z","timestamp":1779882710000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-025-02955-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2955"],"URL":"https:\/\/doi.org\/10.1007\/s00702-025-02955-7","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"assertion":[{"value":"2 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our institution does not require ethical approval for narrative reviews.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}